Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CBIONASDAQ:CYCNNASDAQ:ODTNASDAQ:ONCYNASDAQ:SLS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCatalyst Biosciences$0.77$0.19▼$8.69$291.29M1.05763,526 shs32,246 shsCYCNCyclerion Therapeutics$3.14+13.4%$3.10$1.75▼$6.75$7.51M1.843,174 shs441 shsODTOdonate Therapeutics$1.27$0.85▼$7.10N/AN/AN/A87,682 shsONCYOncolytics Biotech$1.08+1.9%$1.06$0.88▼$3.39$81.45M1.93369,111 shs302,083 shsSLSSELLAS Life Sciences Group$1.52-1.3%$1.19$0.50▼$1.91$85.53M2.351.46 million shs645,326 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCatalyst Biosciences0.00%0.00%0.00%0.00%+3,234.57%CYCNCyclerion Therapeutics+10.95%-2.43%+1.29%+7.17%-44.83%ODTOdonate Therapeutics0.00%0.00%0.00%0.00%0.00%ONCYOncolytics Biotech+1.89%+4.85%+6.93%-11.48%-14.96%SLSSELLAS Life Sciences Group-1.30%0.00%+43.40%+200.40%+4.11%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBIOCatalyst BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONCYOncolytics Biotech1.1311 of 5 stars3.54.00.00.00.60.00.0SLSSELLAS Life Sciences Group0.5274 of 5 stars3.51.00.00.00.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCatalyst BiosciencesN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AONCYOncolytics Biotech3.00Buy$4.00270.37% UpsideSLSSELLAS Life Sciences Group3.00Buy$3.0097.37% UpsideCurrent Analyst RatingsLatest CBIO, ODT, CYCN, SLS, and ONCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024ONCYOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.002/14/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCatalyst Biosciences$790K0.00N/AN/A($0.78) per share0.00CYCNCyclerion Therapeutics$1.62M5.25N/AN/A$4.62 per share0.68ODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/ASLSSELLAS Life Sciences Group$1M85.53N/AN/A($0.25) per share-6.08Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCatalyst Biosciences-$8.24M-$1.38N/AN/AN/AN/A-364.68%-281.68%N/ACYCNCyclerion Therapeutics-$5.26M-$5.51N/A∞N/AN/A-111.79%-74.10%5/9/2024 (Estimated)ODTOdonate Therapeutics-$126.35MN/A0.00N/AN/AN/AN/AN/AN/AONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)SLSSELLAS Life Sciences Group-$37.34M-$1.36N/A∞N/AN/A-2,405.54%-241.00%5/9/2024 (Estimated)Latest CBIO, ODT, CYCN, SLS, and ONCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023SLSSELLAS Life Sciences GroupN/A-$0.25-$0.25-$0.25N/AN/A3/7/2024Q4 2023ONCYOncolytics Biotech-$0.11-$0.04+$0.07-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCatalyst BiosciencesN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCatalyst BiosciencesN/A2.882.88CYCNCyclerion TherapeuticsN/A3.853.85ODTOdonate TherapeuticsN/AN/AN/AONCYOncolytics BiotechN/A9.019.01SLSSELLAS Life Sciences GroupN/A0.230.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCatalyst Biosciences5.98%CYCNCyclerion Therapeutics75.62%ODTOdonate TherapeuticsN/AONCYOncolytics Biotech6.82%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipCBIOCatalyst Biosciences2.92%CYCNCyclerion Therapeutics13.10%ODTOdonate Therapeutics48.90%ONCYOncolytics Biotech0.10%SLSSELLAS Life Sciences Group1.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCatalyst Biosciences737.98 million36.87 millionOptionableCYCNCyclerion Therapeutics12.71 million2.36 millionNo DataODTOdonate Therapeutics14528.53 million14.58 millionNot OptionableONCYOncolytics Biotech2975.42 million75.35 millionNot OptionableSLSSELLAS Life Sciences Group1756.27 million55.37 millionNot OptionableCBIO, ODT, CYCN, SLS, and ONCY HeadlinesSourceHeadlineSellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payoutseekingalpha.com - April 19 at 3:11 PMSeligman Launches a New Health Care Fundinstitutionalinvestor.com - March 28 at 7:32 PMSELLAS Life Sciences Group files for $200M mixed shelfmsn.com - March 28 at 7:32 PMSELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - March 28 at 4:05 PMBuy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financialsmarkets.businessinsider.com - March 27 at 10:54 PMSELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL Studymarkets.businessinsider.com - March 26 at 10:33 AMSELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Studyglobenewswire.com - March 26 at 7:35 AMSELLAS Life Sciences Group Inc.wsj.com - March 21 at 3:15 PMSELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - March 19 at 4:05 PMSELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ETglobenewswire.com - March 19 at 8:47 AMSellas Life Sciences Shares Drop 31% After Direct Offering Pricesmarketwatch.com - March 16 at 2:16 PMGeron, Graphite Bio, Immuneering among healthcare moversmsn.com - March 15 at 10:20 AMSELLAS Life Sciences looks to raise $20M in a direct offeringmsn.com - March 15 at 10:20 AMSellas Announces $20 Mln Registered Direct Offering, Concurrent Private Placementmarkets.businessinsider.com - March 15 at 10:20 AMSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - March 15 at 9:14 AMSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - March 15 at 9:00 AMAadi Bioscience Q4 2023 Earnings Previewseekingalpha.com - March 12 at 12:49 PMSellas Life Sciences Group Inc (SLS)investing.com - March 10 at 5:06 AMSELLAS Life Sciences Group, Inc.: SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnershipsfinanznachrichten.de - March 9 at 3:43 PMSELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnershipsglobenewswire.com - March 8 at 8:00 AMSLS Mar 2024 4.000 putfinance.yahoo.com - March 7 at 11:22 PMSELLAS Life Sciences Group, Inc. (SLS)finance.yahoo.com - March 1 at 3:52 PMSELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conferenceglobenewswire.com - March 1 at 8:30 AMSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Timeglobenewswire.com - February 29 at 8:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCatalyst BiosciencesNASDAQ:CBIOCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Cyclerion TherapeuticsNASDAQ:CYCNCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Odonate TherapeuticsNASDAQ:ODTOdonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').Oncolytics BiotechNASDAQ:ONCYOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.SELLAS Life Sciences GroupNASDAQ:SLSSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.